Nancy Daly is Chief Executive Officer of Conquer Cancer, the ASCO Foundation, the philanthropic arm of the American Society of Clinical Oncology that funds cancer research and supports oncology professionals worldwide. She has led the organisation since 2020 after serving in multiple senior roles including director of cancer research policy, director of grants, and chief philanthropic officer. Conquer Cancer is recognised for funding physician‑scientists and early‑career researchers whose work drives advances in cancer treatment, education and quality of care, and under Daly’s leadership continues to advance its mission to accelerate breakthroughs in lifesaving research globally.
Under her tenure, Conquer Cancer has broadened its global impact by awarding millions of dollars in grants and awards to researchers across countries and career stages, supporting programs such as Young Investigator Awards, Career Development Awards, Global Oncology Young Investigator Awards and other research funding initiatives. With extensive funding for research across the globe, Conquer Cancer continues to strengthen its support for emerging leaders in oncology reinforcing its role as a key funder of cancer research that informs clinical practice and improves patient outcomes worldwide.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
